Elanco Animal Health Incorporated (ELAN) Stock Analysis & Winston Score

Elanco Animal Health makes medicines and other health products for animals. Its customers are pet owners, veterinarians, and farmers who raise livestock like cattle and pigs. The company sells treatments for fleas, ticks, parasites, pain, and various diseases — with well-known pet health brands like Seresto, Credelio, and Interceptor Plus. Elanco earns money by selling its products to veterinary clinics, retailers, and farm supply distributors around the world. It operates globally, with a significant presence in North America, Europe, and other international markets, and generates roughly $4–5 billion in annual revenue. The company carries a heavy debt load from its 2019 acquisition of Bayer's animal health business, which weighs on profitability — its ROIC of 3.8% is low for the industry. The key challenge going forward is paying down that debt while growing its pet health portfolio, as competition from larger rivals like Zoetis and Merck Animal Health remains intense.